Clinical Report: Updated COVID Shot Linked to Added Protection
Overview
Interim data from the CDC-funded VISION Network indicates that the 2025-2026 COVID-19 vaccine provides short-term protection against medically attended COVID-19 in immunocompetent adults. Vaccine effectiveness was estimated at 50% for emergency department and urgent care encounters and 55% for hospitalizations.
Background
The ongoing evolution of COVID-19 necessitates continuous evaluation of vaccine effectiveness, particularly as new variants emerge. The 2025-2026 vaccine formulation specifically targets JN.1 and JN.1-derived sublineages.
Data Highlights
| Outcome | Vaccine Effectiveness |
|---|---|
| ED/UC Encounters | 50% |
| Hospitalizations | 55% |
| ED/UC Encounters (Age 65+) | 48% |
| Hospitalizations (Age 65+) | 53% |
Key Findings
- The 2025-2026 COVID-19 vaccine was associated with 50% effectiveness against COVID-19-related ED/UC encounters.
- Vaccine effectiveness against COVID-19-related hospitalizations was estimated at 55%.
- Among adults aged 65 years or older, vaccine effectiveness was 48% for ED/UC encounters and 53% for hospitalizations.
- The study primarily reflects short-term protection, with median time since vaccination being 47 days for ED/UC encounters.
- Findings suggest that increased population-level immunity may affect vaccine effectiveness estimates.
Clinical Implications
Healthcare providers should consider the short-term effectiveness of the 2025-2026 COVID-19 vaccine when advising patients.
Conclusion
The interim analysis provides data on the effectiveness of the 2025-2026 COVID-19 vaccines in immunocompetent adults.
Related Resources & Content
- CDC, JAMA Network Open, 2026 -- Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design
- CDC, COVID-19 Vaccination Guidance, 2025 -- 2025–2026 COVID-19 Vaccination Guidance
- conexiant — Recent COVID-19 Shot Linked to Less Spread
- ADA News — CDC: Being up to date with COVID-19 vaccines means getting latest booster dose
- dana-farber — COVID-19 vaccine and blood cancer
- The ASCO Post — Study Finds Third COVID-19 Vaccine Dose Effectively Boosts Immunity for Patients With Solid Tumors
- Recent COVID-19 Shot Linked to Less Spread
- CDC: Being up to date with COVID-19 vaccines means getting latest booster dose
- COVID-19 vaccine and blood cancer
- 2025–2026 COVID-19 Vaccination Guidance | Covid | CDC
- Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design | Infectious Diseases | JAMA Network Open | JAMA Network
- Statement on the antigen composition of COVID-19 vaccines
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
